Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
Barinthus生物醫藥公司在2024年EASL國際肝病大會上公佈了兩項慢性乙型肝炎臨床試驗的最新數據。
- In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation.
- In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, a statistically significant difference was observed in HBsAg levels between the VTP-300 treatment and placebo groups at 24-weeks post-end of treatment (EOT) and 84% of participants who received VTP-300 discontinued standard of care (SoC) NUC therapy vs 53% receiving placebo.
- 在HBV003試驗中，67%的參與者的HBsAg水平小於10 IU/mL，19%的參與者在NUC停藥評估（治療結束或之後）時HBsAg不可檢測，76%的參與者符合核苷（酸）類似物（NUC）治療停藥標準。
- 在與arbutus biopharma合作進行的IM-PROVE II試驗中，在治療結束後24周，VTP-300治療組與安慰劑組之間的HBsAg水平存在統計學差異。治療結束後（EOT），接受VTP-300治療的84%的參與者停止了標準板NUC治療，而接受安慰劑的53%的參與者停止了NUC治療。接受標準板NUC治療的53%的參與者停止了NUC治療，而接受安慰劑的84%的參與者停止了VTP-300治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。